<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271514</url>
  </required_header>
  <id_info>
    <org_study_id>RPT193-01</org_study_id>
    <nct_id>NCT04271514</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAPT Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAPT Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind,&#xD;
      placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male&#xD;
      and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and&#xD;
      selective antagonist of CCR4.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Actual">April 26, 2021</completion_date>
  <primary_completion_date type="Actual">April 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>up to Day 16 (Part A: SAD); up to Day 22 (Part B: MAD); up to Day 43 (Part C)</time_frame>
    <description>Number of participants with abnormal laboratory values and/or adverse events that are related to treatment</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of RPT193 will be administered to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered once/day for 7 days to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMPLETED ENROLLMENT -- Expansion Part C - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT193 will be administered daily for 28 days to patients with atopic dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMPLETED ENROLLMENT -- Expansion Part C - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered daily for 28 days to patients with atopic dermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPT193</intervention_name>
    <description>Antagonist of the CCR4 chemokine receptor</description>
    <arm_group_label>COMPLETED ENROLLMENT -- Expansion Part C - active</arm_group_label>
    <arm_group_label>COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active</arm_group_label>
    <arm_group_label>COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>COMPLETED ENROLLMENT -- Expansion Part C - placebo</arm_group_label>
    <arm_group_label>COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo</arm_group_label>
    <arm_group_label>COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selected Inclusion Criteria:&#xD;
&#xD;
        Parts A &amp; B (COMPLETED ENROLLMENT):&#xD;
&#xD;
          -  Healthy male or female&#xD;
&#xD;
          -  18-55 years of age, inclusive&#xD;
&#xD;
          -  At least 50 kg in weight&#xD;
&#xD;
          -  BMI: 18.0-30.0 kg/m2, inclusive&#xD;
&#xD;
        Part C (COMPLETED ENROLLMENT):&#xD;
&#xD;
          -  Male or female with atopic dermatitis&#xD;
&#xD;
          -  18-65 years of age, inclusive&#xD;
&#xD;
          -  BMI between 18.0 (inclusive) and &lt;40.0 kg/m2&#xD;
&#xD;
          -  Body surface area (BSA) with AD involvement ≥10%&#xD;
&#xD;
          -  Eczema Area and Severity Index (EASI) score ≥12&#xD;
&#xD;
          -  Validated Investigator's Global Assessment (vIGA) ≥3&#xD;
&#xD;
          -  History of inadequate response to treatment with topical medications, such as&#xD;
             corticosteroids or calcineurin inhibitors, or patients for whom topical treatments are&#xD;
             otherwise medically inadvisable&#xD;
&#xD;
        Selected Exclusion Criteria:&#xD;
&#xD;
        Parts A &amp; B (COMPLETED ENROLLMENT):&#xD;
&#xD;
          -  Use of tobacco products within 60 days prior to drug administration&#xD;
&#xD;
          -  History of alcohol abuse or drug addiction&#xD;
&#xD;
          -  Positive drug and alcohol screen&#xD;
&#xD;
          -  Participation in a drug study within 60 days prior to drug administration&#xD;
&#xD;
          -  Donation or loss of more than 100 mL of blood within 60 days prior to drug&#xD;
             administration.&#xD;
&#xD;
          -  Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0&#xD;
             liters of blood (for female subjects) in the 10 months prior to drug administration.&#xD;
&#xD;
        Part C (COMPLETED ENROLLMENT):&#xD;
&#xD;
          -  Any serious and/or uncontrolled medical condition&#xD;
&#xD;
          -  History of alcohol abuse or drug addiction&#xD;
&#xD;
          -  Positive drug and alcohol screen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Cheng, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RAPT Therepeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perseverance Research Center LLC</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenus Research &amp; Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management,LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroBoston Clinical Partners LLC</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

